Product of the week
ELIQUIS (apixaban), an oral direct factor Xa inhibitor, is now PBS listed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE, in adult patients.
DVT and PE are serious cardiovascular conditions associated with more than 5000 deaths every year in Australia.
The recommended dose of ELIQUIS for the treatment of acute DVT/PE is 10mg twice daily for seven days, followed by 5mg twice daily, taken orally. The recommended dose for the prevention of recurrent DVT/PE is 2.5mg taken orally twice daily after at least 6 months of treatment for DVT/PE.
Refer to the